TME Pharma N.V. Asset Resilience Ratio

Latest as of December 2025: 0.19%

TME Pharma N.V. asset resilience ratio. TME Pharma N.V. (ALTME) has an Asset Resilience Ratio of 0.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TME Pharma N.V. (ALTME) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€4.00K

≈ $4.68K USD Cash + Short-term Investments

Total Assets

€2.14 Million

≈ $2.50 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of TME Pharma N.V. (2015–2025)

Asset resilience ratio of TME Pharma N.V. from 2015 to 2025. This chart shows how TME Pharma N.V.'s Asset Resilience Ratio has changed over time. Read TME Pharma N.V. (ALTME) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down TME Pharma N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TME Pharma N.V. balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€4.00K	0.19%
Total Liquid Assets	€4.00K	0.19%

Asset Resilience Insights

Limited Liquidity: TME Pharma N.V. maintains only 0.19% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

TME Pharma N.V. Industry Peers by Asset Resilience Ratio

Compare TME Pharma N.V.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	36.07%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
3SBio Inc F:83B	Biotechnology	10.64%

TME Pharma N.V. Asset Resilience Ratio by Year (2015–2025)

TME Pharma N.V. asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for TME Pharma N.V..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.19%	€4.00K ≈ $4.68K	€2.14 Million ≈ $2.50 Million	-95.09pp
2024-12-31	95.27%	€3.25 Million ≈ $3.79 Million	€3.41 Million ≈ $3.98 Million	+5.15pp
2023-12-31	90.12%	€2.25 Million ≈ $2.62 Million	€2.49 Million ≈ $2.91 Million	+1.71pp
2022-12-31	88.42%	€4.63 Million ≈ $5.42 Million	€5.24 Million ≈ $6.13 Million	-8.67pp
2021-12-31	97.09%	€9.48 Million ≈ $11.09 Million	€9.77 Million ≈ $11.42 Million	+0.11pp
2020-12-31	96.98%	€10.33 Million ≈ $12.08 Million	€10.65 Million ≈ $12.46 Million	+15.40pp
2019-12-31	81.58%	€1.41 Million ≈ $1.65 Million	€1.73 Million ≈ $2.02 Million	-13.99pp
2018-12-31	95.57%	€4.32 Million ≈ $5.05 Million	€4.52 Million ≈ $5.28 Million	+12.86pp
2016-12-31	82.71%	€2.37 Million ≈ $2.77 Million	€2.87 Million ≈ $3.35 Million	+80.08pp
2015-12-31	2.63%	€159.00K ≈ $185.89K	€6.04 Million ≈ $7.06 Million	--

pp = percentage points

About TME Pharma N.V.

PA:ALTME France Biotechnology

Market Cap

$11.79 Million

€10.09 Million EUR

Market Cap Rank

#27652 Global

#483 in France

Share Price

€0.11

Change (1 day)

-4.29%

52-Week Range

€0.05 - €0.16

All Time High

€1994.22